Atria Investments Inc Has $794,000 Position in Integer Holdings Co. (NYSE:ITGR)

Atria Investments Inc trimmed its position in Integer Holdings Co. (NYSE:ITGR) by 5.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 6,105 shares of the medical equipment provider’s stock after selling 323 shares during the period. Atria Investments Inc’s holdings in Integer were worth $794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. grew its stake in shares of Integer by 55.9% in the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 80 shares in the last quarter. Quest Partners LLC boosted its holdings in Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 332 shares during the period. GAMMA Investing LLC grew its position in shares of Integer by 60.9% during the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 142 shares in the last quarter. Innealta Capital LLC bought a new position in shares of Integer during the second quarter worth approximately $110,000. Finally, Hancock Whitney Corp acquired a new stake in shares of Integer in the first quarter valued at approximately $203,000. Institutional investors own 99.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ITGR. Truist Financial reduced their price target on Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Piper Sandler restated an “overweight” rating and issued a $140.00 price target (up previously from $125.00) on shares of Integer in a research report on Friday, October 25th. Bank of America upped their price objective on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. KeyCorp raised their target price on shares of Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Finally, Benchmark upped their price target on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $139.75.

Integer Stock Up 1.0 %

ITGR stock opened at $134.55 on Tuesday. The firm has a 50-day moving average price of $129.20 and a 200-day moving average price of $122.75. Integer Holdings Co. has a 12 month low of $84.75 and a 12 month high of $140.91. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $4.51 billion, a P/E ratio of 41.10, a price-to-earnings-growth ratio of 1.91 and a beta of 1.09.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The business had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.27 EPS. As a group, equities research analysts anticipate that Integer Holdings Co. will post 5.34 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.